Citadel Advisors
NVO

Citadel Advisors’s Novo Nordisk NVO Stock Holding History

Citadel Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$288M Sell
7,833,400
-7,553,900
-49% -$358M 0.05% 319
2025
Q4 		$783M Buy
15,387,300
+4,948,900
+47% +$253M 0.12% 110
2025
Q3 		$579M Buy
10,438,400
+6,561,900
+169% +$384M 0.09% 147
2025
Q2 		$268M Buy
3,876,500
+380,700
+11% +$25.9M 0.05% 312
2025
Q1 		$243M Buy
3,495,800
+1,212,600
+53% +$100M 0.05% 307
2024
Q4 		$196M Buy
2,283,200
+940,400
+70% +$102M 0.03% 415
2024
Q3 		$160M Sell
1,342,800
-440,000
-25% -$58.7M 0.03% 459
2024
Q2 		$254M Sell
1,782,800
-200,200
-10% -$26.5M 0.05% 274
2024
Q1 		$255M Buy
1,983,000
+822,600
+71% +$97.9M 0.05% 288
2023
Q4 		$120M Buy
1,160,400
+54,100
+5% +$5.35M 0.02% 583
2023
Q3 		$101M Buy
1,106,300
+172,300
+18% +$15.2M 0.02% 626
2023
Q2 		$75.6M Buy
934,000
+203,800
+28% +$16.6M 0.02% 780
2023
Q1 		$58.1M Buy
730,200
+223,800
+44% +$15.9M 0.01% 957
2022
Q4 		$34.3M Sell
506,400
-182,600
-27% -$10.7M 0.01% 1432
2022
Q3 		$34.3M Buy
689,000
+325,800
+90% +$17.5M 0.01% 1360
2022
Q2 		$20.2M Buy
363,200
+16,200
+5% +$899K 0.01% 1843
2022
Q1 		$19.3M Buy
347,000
+69,000
+25% +$3.54M ﹤0.01% 2027
2021
Q4 		$15.6M Sell
278,000
-400
-0.1% -$21.7K ﹤0.01% 2357
2021
Q3 		$13.4M Buy
278,400
+68,400
+33% +$3.31M ﹤0.01% 2596
2021
Q2 		$8.8M Buy
210,000
+29,800
+17% +$1.16M ﹤0.01% 3293
2021
Q1 		$6.08M Sell
180,200
-92,400
-34% -$3.29M ﹤0.01% 3847
2020
Q4 		$9.52M Buy
272,600
+85,800
+46% +$2.97M ﹤0.01% 2704
2020
Q3 		$6.49M Sell
186,800
-64,600
-26% -$2.15M ﹤0.01% 2802
2020
Q2 		$8.23M Buy
251,400
+87,600
+53% +$2.8M ﹤0.01% 2451
2020
Q1 		$4.93M Buy
163,800
+14,600
+10% +$435K ﹤0.01% 2728
2019
Q4 		$4.32M Sell
149,200
-22,400
-13% -$620K ﹤0.01% 3260
2019
Q3 		$4.44M Sell
171,600
-27,400
-14% -$693K ﹤0.01% 3274
2019
Q2 		$5.08M Sell
199,000
-17,200
-8% -$425K ﹤0.01% 3055
2019
Q1 		$5.66M Buy
216,200
+12,800
+6% +$315K ﹤0.01% 2826
2018
Q4 		$4.68M Buy
203,400
+103,400
+103% +$2.3M ﹤0.01% 2882
2018
Q3 		$2.36M Sell
100,000
-211,400
-68% -$5.16M ﹤0.01% 4129
2018
Q2 		$7.18M Buy
311,400
+215,400
+224% +$5.12M ﹤0.01% 2301
2018
Q1 		$2.36M Sell
96,000
-35,800
-27% -$940K ﹤0.01% 3477
2017
Q4 		$3.54M Buy
131,800
+92,600
+236% +$2.35M ﹤0.01% 2892
2017
Q3 		$944K Sell
39,200
-51,400
-57% -$1.16M ﹤0.01% 4404
2017
Q2 		$1.94M Sell
90,600
-106,200
-54% -$2.14M ﹤0.01% 3201
2017
Q1 		$3.37M Sell
196,800
-170,800
-46% -$2.97M ﹤0.01% 2462
2016
Q4 		$6.59M Buy
367,600
+213,600
+139% +$3.87M 0.01% 1716
2016
Q3 		$3.2M Buy
154,000
+101,000
+191% +$2.5M ﹤0.01% 2435
2016
Q2 		$1.43M Buy
+53,000
New +$1.45M ﹤0.01% 3126

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Citadel Advisors's NVO Position: Q1 2026 in Review

Citadel Advisors reduced its Novo Nordisk (NVO) stake by 63% in Q1 2026, selling an estimated $221M and leaving 2,736,525 shares worth $101M. The position accounts for 0.02% of the portfolio, ranked #805.

Citadel Advisors first reported a position in NVO in Q3 2014 and has held it in 45 quarters since. The position peaked at $377M in Q4 2025. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Citadel Advisors held 2,736,525 shares of Novo Nordisk worth $101M as of Q1 2026.
  • Citadel Advisors sold 4,674,398 Novo Nordisk shares in Q1 2026, an estimated $221M.
  • Novo Nordisk made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #805 holding.
  • Citadel Advisors first reported a position in Novo Nordisk in Q3 2014 and has held it in 45 quarters since.
  • Citadel Advisors's Novo Nordisk position peaked at $377M in Q4 2025.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.